Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 8, 2011, Pages 999-1007

  Alipour, Misagh ^a,b   Dorval, Crystal ^a   Suntres, Zacharias E ^a,b   Omri, Abdelwahab ^a  

^a LAURENTIAN UNIVERSITY   (Canada)

^b LAKEHEAD UNIVERSITY   (Canada)

Author keywords

Antibiotics; Bacteria; Biofilms; Cystic fibrosis; Exopolysaccharides

Indexed keywords

ALGINATE LYASE; ANTIINFECTIVE AGENT; BACTERIAL ENZYME; BACTERICIDE; LIPOSOME; TOBRAMYCIN BISMUTH ETHANEDITHIOL; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BIOFILM; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG POTENTIATION; IMMUNOGOLD LABELING; NONHUMAN; PSEUDOMONAS AERUGINOSA; TRANSMISSION ELECTRON MICROSCOPY; X RAY SPECTROMETRY;

ALGINATES; ANTI-BACTERIAL AGENTS; BIOFILMS; BISMUTH; DRUG COMBINATIONS; LIPOSOMES; LYASES; MERCAPTOETHANOL; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

EID: 79959905442     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01304.x     Document Type: Article

References (49)

1. Hoiby N et al. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010; 35: 322-332.
2. Bjarnsholt T et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 2009; 44: 547-558.
3. Kreindler JL. Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies. Pharmacol Ther 2010; 125: 219-229.
4. Kater A et al. The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin beta 4. Ann N Y Acad Sci 2007; 1112: 140-153. (Pubitemid 47598647)
5. Landry RM et al. Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance. Mol Microbiol 2006; 59: 142-151.
6. Ramsey DM, Wozniak DJ. Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. Mol Microbiol 2005; 56: 309-322. (Pubitemid 40516773)
7. Behrends V et al. Metabolic profiling of Pseudomonas aeruginosa demonstrates that the anti-sigma factor MucA modulates osmotic stress tolerance. Mol Biosyst 2010; 6: 562-569.
8. Bragonzi A et al. Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model. J Infect Dis 2005; 192: 410-419. (Pubitemid 41023119)
9. Qiu D et al. Regulated proteolysis controls mucoid conversion in Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 2007; 104: 8107-8112. (Pubitemid 47185883)
10. Damron FH et al. The Pseudomonas aeruginosa sensor kinase KinB negatively controls alginate production through AlgW-dependent MucA proteolysis. J Bacteriol 2009; 191: 2285-2295.
11. Jain S, Ohman DE. Role of an alginate lyase for alginate transport in mucoid Pseudomonas aeruginosa. Infect Immun 2005; 73: 6429-6436. (Pubitemid 41368804)
12. Jackson KD et al. Identification of psl, a locus encoding a potential exopolysaccharide that is essential for Pseudomonas aeruginosa PAO1 biofilm formation. J Bacteriol 2004; 186: 4466-4475. (Pubitemid 38891009)
13. Ma L et al. Pseudomonas aeruginosa Psl is a galactose- and mannose-rich exopolysaccharide. J Bacteriol 2007; 189: 8353-8356. (Pubitemid 350178948)
14. Wozniak DJ et al. Alginate is not a significant component of the extracellular polysaccharide matrix of PA14 and PAO1 Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci U S A 2003; 100: 7907-7912. (Pubitemid 36760068)
15. Abdi-Ali A et al. Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa. Int J Antimicrob Agents 2006; 27: 196-200. (Pubitemid 43246948)
16. Pier GB et al. Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis. Infect Immun 2001; 69: 1895-1901. (Pubitemid 32187652)
17. Cardenas S et al. Neurotrophic and neuroimmune responses to early-life Pseudomonas aeruginosa infection in rat lungs. Am J Physiol Lung Cell Mol Physiol 2010; 299: L334-L344.
18. Firoved AM, Deretic V. Microarray analysis of global gene expression in mucoid Pseudomonas aeruginosa. J Bacteriol 2003; 185: 1071-1081. (Pubitemid 36139466)
19. Chattoraj SS et al. Pseudomonas aeruginosa alginate promotes Burkholderia cenocepacia persistence in cystic fibrosis transmembrane conductance regulator knockout mice. Infect Immun 2010; 78: 984-993.
20. Hoffman LR et al. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005; 436: 1171-1175. (Pubitemid 41232296)
21. Bagge N et al. Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal beta-lactamase. APMIS 2000; 108: 589-600.
22. Bagge N et al. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production. Antimicrob Agents Chemother 2004; 48: 1175-1187. (Pubitemid 38405471)
23. Wood LF et al. Cell wall-inhibitory antibiotics activate the alginate biosynthesis operon in Pseudomonas aeruginosa: roles of sigma (AlgT) and the AlgW and Prc proteases. Mol Microbiol 2006; 62: 412-426. (Pubitemid 44477231)
24. Stratton CW et al. Bismuth-mediated disruption of the glycocalyx-cell wall of Helicobacter pylori: ultrastructural evidence for a mechanism of action for bismuth salts. J Antimicrob Chemother 1999; 43: 659-666. (Pubitemid 29231691)
25. Kotani T et al. Antibacterial properties of some cyclic organobismuth(III) compounds. Antimicrob Agents Chemother 2005; 49: 2729-2734. (Pubitemid 40917585)
26. Dodge AG, Wackett LP. Metabolism of bismuth subsalicylate and intracellular accumulation of bismuth by Fusarium sp. strain BI. Appl Environ Microbiol 2005; 71: 876-882. (Pubitemid 40223575)
27. Nadeau OW et al. Deposition of bismuth by Yersinia enterocolitica. Med Microbiol Immunol 1992; 181: 145-152.
28. Domenico P et al. Enhancement of bismuth antibacterial activity with lipophilic thiol chelators. Antimicrob Agents Chemother 1997; 41: 1697-1703. (Pubitemid 27339870)
29. Veloira WG et al. In vitro activity and synergy of bismuth thiols and tobramycin against Burkholderia cepacia complex. J Antimicrob Chemother 2003; 52: 915-919. (Pubitemid 38008410)
30. Domenico P et al. Resistance to bismuth among gram-negative bacteria is dependent upon iron and its uptake. J Antimicrob Chemother 1996; 38: 1031-1040. (Pubitemid 27073282)
31. Huang CT, Stewart PS. Reduction of polysaccharide production in Pseudomonas aeruginosa biofilms by bismuth dimercaprol (BisBAL) treatment. J Antimicrob Chemother 1999; 44: 601-605. (Pubitemid 29532837)
32. Wu CL et al. Subinhibitory bismuth-thiols reduce virulence of Pseudomonas aeruginosa. Am J Respir Cell Mol Biol 2002; 26: 731-738.
33. Hatch RA, Schiller NL. Alginate lyase promotes diffusion of aminoglycosides through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998; 42: 974-977. (Pubitemid 28216397)
34. Hay ID et al. Impact of alginate overproduction on attachment and biofilm architecture of a supermucoid Pseudomonas aeruginosa strain. Appl Environ Microbiol 2009; 75: 6022-6025.
35. Boyd A, Chakrabarty AM. Role of alginate lyase in cell detachment of Pseudomonas aeruginosa. Appl Environ Microbiol 1994; 60: 2355-2359. (Pubitemid 24205731)
36. Albrecht MT, Schiller NL. Alginate lyase (AlgL) activity is required for alginate biosynthesis in Pseudomonas aeruginosa. J Bacteriol 2005; 187: 3869-3872. (Pubitemid 40705594)
37. Alkawash MA et al. Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms. APMIS 2006; 114: 131-138. (Pubitemid 43356924)
38. Tielen P et al. Alginate acetylation influences initial surface colonization by mucoid Pseudomonas aeruginosa. Microbiol Res 2005; 160: 165-176. (Pubitemid 40406351)
39. Halwani M et al. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin. Int J Pharm 2008; 358: 278-284.
40. Alipour M et al. Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuthethanedithiol with tobramycin in liposomes. J Antimicrob Chemother 2010; 65: 684-693.
41. Alipour M et al. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J Antimicrob Chemother 2009; 64: 317-325.
42. Alipour M et al. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int J Pharm 2008; 355: 293-298.
43. Moser C et al. Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis. APMIS 2009; 117: 95-107.
44. van Gennip M et al. Augmented effect of early antibiotic treatment in mice with experimental lung infections due to sequentially adapted mucoid strains of Pseudomonas aeruginosa. J Antimicrob Chemother 2009; 64: 1241-1250.
45. Kobayashi H et al. Pathogenesis and clinical manifestations of chronic colonization by Pseudomonas aeruginosa and its biofilms in the airway tract. J Infect Chemother 2009; 15: 125-142.
46. Strathmann M et al. Application of fluorescently labelled lectins for the visualization and biochemical characterization of polysaccharides in biofilms of Pseudomonas aeruginosa. J Microbiol Methods 2002; 50: 237-248. (Pubitemid 34603268)
47. Schaber JA et al. Pseudomonas aeruginosa forms biofilms in acute infection independent of cell-to-cell signaling. Infect Immun 2007; 75: 3715-3721. (Pubitemid 47206268)
48. Hunter RC, Beveridge TJ. High-resolution visualization of Pseudomonas aeruginosa PAO1 biofilms by freeze-substitution transmission electron microscopy. J Bacteriol 2005; 187: 7619-7630. (Pubitemid 41587700)
49. Mahony DE et al. Antimicrobial activities of synthetic bismuth compounds against Clostridium difficile. Antimicrob Agents Chemother 1999; 43: 582-588. (Pubitemid 29109522)